Individuals Discontinuing Anti-Obesity Medications Put On Pounds at a Quadrupled Rate Than People Using Diet and Exercise

A recent study reveals that people who come off blockbuster slimming jabs like Wegovy and Mounjaro tend to recover shed pounds at a significantly accelerated pace than those who halt conventional diet and exercise programs.

Published data in a prominent medical journal shows that while obese individuals frequently drop about a fifth of their body weight while undergoing treatment, the mass comes back at an average rate of nearly a kilo each month once they quit.

"People purchasing such treatments should be cognizant of the danger of rapid rebound weight gain when the treatment is stopped," stated researcher Dr. Susan Jebb.

That rate of recovery suggests a return to pre-treatment weight within about a year and a half.

Analyzing Treatments

The research, which reviewed 37 of studies involving thousands of participants, compared the results of the injectable medications with older methods.

Researchers point out that people who shed pounds through diet and exercise usually see a more gradual weight regain—perhaps 0.1 kg a month—post-intervention.

The Reason for the Rapid Regain

Experts suggest the mode of action of the jabs explains the amplified rebound.

The injections copy a natural hormone called glucagon-like peptide-1, which controls appetite.

"Long-term administration of GLP-1 concentrations far above than the body's typical production may cause the body to produce less of its own natural GLP-1, and could reduce responsiveness to its effects," noted Dr. Adam Collins, a nutrition expert.

"Stopping of this GLP-1 'fix' results in hunger is unsuppressed, making overeating a significant risk."

A Chronic Issue?

Medical guidelines advise the jabs for people with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.

Many experts contend that, given the significant potential of relapse, the therapy should be considered long-term.

This view is reinforced by pharmaceutical companies, who say that the findings "underscore the long-term character of obesity," comparing it to managing conditions like diabetes.

User Accounts

Users who have come off the jabs report a sudden resurgence of cravings.

"It felt as if a trigger flipping and you're instantly starving," described an individual.

This challenge is compounded if patients have not developed lasting lifestyle or habit changes during therapy.

Significant Adoption

Figures show that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with interest continuing to grow.

• Use is greater among women compared to males.
• The 40s and 50s demographic shows the highest level of interest.
• Many access the drugs through private healthcare rather than the NHS.

In conclusion, clinicians stress that while these medications are potent agents for shedding pounds, they are not a magic solution and long-term success likely depends on integrated behavioural changes.